{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:15:05Z","timestamp":1792178105259,"version":"4.4.0"},"reference-count":56,"publisher":"National Institute for Health and Care Research","issue":"47","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["10\/104\/20"],"award-info":[{"award-number":["10\/104\/20"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>Data suggest that approximately 50,000 adults with learning disabilities (LDs) in England and Wales are currently prescribed antipsychotic medication. Illness in this population is common, including significant rates of challenging behaviour and mental illness, but there is particular concern over the use of antipsychotics prescribed for reasons other than the treatment of psychosis. Control of challenging behaviour is the primary reason why such medications are prescribed despite the absence of good evidence for any therapeutic effect for this purpose.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To assess the feasibility of recruitment and retention and to explore non-efficacy-based barriers to a blinded antipsychotic medication withdrawal programme for adults with LDs without psychosis compared with treatment as usual. A secondary objective was to compare trial arms regarding clinical outcomes.<\/jats:p><\/jats:sec>Design<\/jats:title>A two-arm individually randomised double-blind placebo-controlled drug reduction trial.<\/jats:p><\/jats:sec>Setting<\/jats:title>Recruitment was through community learning disability teams (CLDTs) in south Wales and south-west England.<\/jats:p><\/jats:sec>Participants<\/jats:title>Adults with LDs who are prescribed risperidone for treatment of challenging behaviour with no known current psychosis or previous recurrence of psychosis following prior drug reduction.<\/jats:p><\/jats:sec>Intervention<\/jats:title>A double-blind drug reduction programme leading to full withdrawal within 6 months. Treatment in the intervention group was gradually reduced over a 6-month period and then maintained at the same level for a further 3 months, still under blind conditions. In the control group, the baseline level of medication was maintained throughout the 9-month period. The blind was broken at 9 months, following final data collection.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>Feasibility outcomes were (1) the number and proportion of general practices\/CLDTs that progressed from initial approach to recruitment of participants and (2) the number and proportion of recruited participants who progressed through the various stages of the study. Trial arms were also compared regarding clinical outcomes, the Modified Overt Aggression Scale, the Aberrant Behaviour Checklist, the Psychiatric Assessment Schedule for Adults with Developmental Disability checklist, the Antipsychotic Side-effect Checklist, the Dyskinesia Identification System Condensed User Scale, the Client Service Receipt Inventory, use of other interventions to manage challenging behaviour, use of as-required (pro re nata) medication and level of psychotropic medication use.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 22 participants randomised (intervention,n<\/jats:italic>\u2009=\u200911; control,n<\/jats:italic>\u2009=\u200911), 13 (59%) achieved progression through all four stages of reduction. Follow-up data at 6 and 9 months were obtained for 17 participants (intervention,n<\/jats:italic>\u2009=\u200910; and control,n<\/jats:italic>\u2009=\u20097; 77% of those randomised). There were no clinically important changes in participants\u2019 levels of aggression or challenging behaviour at the end of the study. There were no expedited safety reports. Four adverse events and one serious adverse event were reported during the trial.<\/jats:p><\/jats:sec>Limitations<\/jats:title>Recruitment was challenging, which was largely a result of difficulty in identifying appropriate persons to consent and carer concerns regarding re-emergence of challenging behaviour. Reduced recruitment meant that the full trial became an exploratory pilot study.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The results indicate that drug reduction is possible and safe. However, concerns about taking part were probably exacerbated by limited availability of alternative (behavioural) interventions to manage behaviour; therefore, focused support and alternative interventions are required. The results of the qualitative study provide important insights into the experiences of people taking part in drug reduction studies that should influence future trial development.<\/jats:p><\/jats:sec>Future work<\/jats:title>We recommend that further work focuses on support for practitioners, carers and patients in reducing antipsychotic medication.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>Current Controlled Trials ISRCTN38126962.<\/jats:p><\/jats:sec>Funding<\/jats:title>This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 21, No. 47. See the NIHR Journals Library website for further project information.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta21470","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T11:41:52Z","timestamp":1504179712000},"page":"1-92","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities"],"prefix":"10.3310","volume":"21","clinical-trial-number":[{"clinical-trial-number":"isrctn38126962","registry":"10.18810\/isrctn","type":"results"}],"author":[{"given":"Rachel","family":"McNamara","sequence":"first","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Randell","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gillespie","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Population Medicine, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Felce","sequence":"additional","affiliation":[{"name":"Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Romeo","sequence":"additional","affiliation":[{"name":"Centre for the Economics of Mental Health, Institute of Psychiatry, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianna","family":"Angel","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Espinasse","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Biomedical Research Centre \u2013 Clinical Trials Unit, Royal Marsden Hospital NHS Foundation Trust, Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Hood","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Davies","sequence":"additional","affiliation":[{"name":"Community Learning Disability Team, 2gether NHS Foundation Trust, Rotherwas, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Meek","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Addison","sequence":"additional","affiliation":[{"name":"Centre for Trials Research, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Deslandes","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allen","sequence":"additional","affiliation":[{"name":"The Tizard Centre, University of Kent, Canterbury, UK"},{"name":"Positive Response Training & Consultancy, Penryn, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Knapp","sequence":"additional","affiliation":[{"name":"Personal Social Services Research Unit, London School of Economics, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Thapar","sequence":"additional","affiliation":[{"name":"Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kerr","sequence":"additional","affiliation":[{"name":"Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2017,8]]},"reference":[{"key":"key2017083010352486_ref1-bib1","volume-title":"Local Government Data Unit 2011","author":"InfoBaseCymru"},{"key":"key2017083010352486_ref1-bib2","volume-title":"CEDR Research Report 2008 (1): People with Learning Disabilities in England","author":"Emerson","year":"2008"},{"key":"key2017083010352486_ref1-bib3","volume-title":"Monitoring the Public Health Impact of Health Checks for Adults with a Learning Disability in Wales","author":"Perry","year":"2010"},{"key":"key2017083010352486_ref1-bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1468-3148.1999.tb00049.x","article-title":"Prescription of psychotropic medication to people with intellectual disabilities in primary health-care settings","volume":"12","author":"Molyneux","year":"1999","journal-title":"J Appl Res Intellect Disabil"},{"key":"key2017083010352486_ref1-bib5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10803-012-1617-6","article-title":"Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study","volume":"43","author":"Tsiouris","year":"2013","journal-title":"J Autism Dev Disord"},{"key":"key2017083010352486_ref1-bib6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s00127-007-0197-9","article-title":"Psychosis and adults with intellectual disabilities. Prevalence, incidence, and related factors","volume":"42","author":"Cooper","year":"2007","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"key2017083010352486_ref1-bib7","doi-asserted-by":"crossref","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"BMJ"},{"key":"key2017083010352486_ref1-bib8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2788.1990.tb01549.x","article-title":"Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings","volume":"34","author":"Clarke","year":"1990","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1046\/j.1365-2788.2000.00307.x","article-title":"Receipt of psychotropic medication by people with intellectual disability in residential settings","volume":"44","author":"Robertson","year":"2000","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2788.2009.01232.x","article-title":"Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?","volume":"54","author":"Tsiouris","year":"2010","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib11","volume-title":"The HARC Challenging Behaviour Project. Report 5: Treatment, Management and Service Utilisation","author":"Emerson","year":"1997"},{"key":"key2017083010352486_ref1-bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2788.1995.tb00518.x","article-title":"The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour","volume":"39","author":"Kiernan","year":"1995","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3148.2010.00567.x","article-title":"Resettlement outcomes for people with severe challenging behaviour moving from institutional to community living","volume":"24","author":"Perry","year":"2011","journal-title":"J Appl Res Intellect Disabil"},{"key":"key2017083010352486_ref1-bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2788.2005.00663.x","article-title":"Treatment and management of challenging behaviours in congregate and noncongregate community-based supported accommodation","volume":"49","author":"Robertson","year":"2005","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib15","volume-title":"Prescribing of Psychotropic Drugs to People with Learning Disabilities andor Autism by General Practitioners in England","author":"Glover","year":"2015"},{"key":"key2017083010352486_ref1-bib16","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2788.2010.01353.x","article-title":"Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems","volume":"55","author":"Scheifes","year":"2011","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1046\/j.1365-2788.1999.043005360.x","article-title":"Antipsychotic medication for challenging behaviour in people with intellectual disability: a systematic review of randomized controlled trials","volume":"43","author":"Brylewski","year":"1999","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.ridd.2008.08.007","article-title":"Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: an overview","volume":"30","author":"Matson","year":"2009","journal-title":"Res Dev Disabil"},{"key":"key2017083010352486_ref1-bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.rasd.2014.03.021","article-title":"Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: a systematic review","volume":"8","author":"Sawyer","year":"2014","journal-title":"Res Autism Spectr Disord"},{"key":"key2017083010352486_ref1-bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(08)60072-0","article-title":"Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial","volume":"371","author":"Tyrer","year":"2008","journal-title":"Lancet"},{"key":"key2017083010352486_ref1-bib21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2788.2009.01180.x","article-title":"The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis","volume":"53","author":"Romeo","year":"2009","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ridd.2008.10.010","article-title":"Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities","volume":"30","author":"de Leon","year":"2009","journal-title":"Res Dev Disabil"},{"key":"key2017083010352486_ref1-bib23","first-page":"133","article-title":"Neuroleptics","volume-title":"Psychotropic Medication and Developmental Disabilities: The Internatinal Consensus Handbook","author":"Baumeister","year":"1998"},{"key":"key2017083010352486_ref1-bib24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1192\/bjp.bp.110.085670","article-title":"Safety of antipsychotics in people with intellectual disability","volume":"199","author":"Frighi","year":"2011","journal-title":"Br J Psychiatry"},{"key":"key2017083010352486_ref1-bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"key":"key2017083010352486_ref1-bib26","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ridd.2010.05.006","article-title":"An examination of psychotropic medication side effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID?","volume":"31","author":"Mahan","year":"2010","journal-title":"Res Dev Disabil"},{"issue":"13","key":"key2017083010352486_ref1-bib27","doi-asserted-by":"crossref","DOI":"10.3310\/hta7130","article-title":"A systematic review of atypical antipsychotic drugs in schizophrenia","volume":"7","author":"Bagnall","year":"2003","journal-title":"Health Technol Assess"},{"key":"key2017083010352486_ref1-bib28","volume-title":"The Use of Antipsychotic Medication for People with Dementia: Time for Action","author":"Banerjee","year":"2009"},{"key":"key2017083010352486_ref1-bib29","doi-asserted-by":"publisher","first-page":"a1227","DOI":"10.1136\/bmj.a1227","article-title":"Exposure to antipsychotics and risk of stroke: self controlled case series study","volume":"337","author":"Douglas","year":"2008","journal-title":"BMJ"},{"key":"key2017083010352486_ref1-bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1474-4422(08)70295-3","article-title":"The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial","volume":"8","author":"Ballard","year":"2009","journal-title":"Lancet"},{"key":"key2017083010352486_ref1-bib31","volume-title":"Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities whose Behaviour Challenges","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2017083010352486_ref1-bib32","volume-title":"Winterbourne Medicines Programme: Improving the Use of Medicines in People with Learning Disabilities \u2013 NHS Improving Quality Report Apr2014\u2013Apr2015","author":"NHS England","year":"2015"},{"key":"key2017083010352486_ref1-bib33","volume-title":"Mental Health Act 2007","author":"Great Britain","year":"2005"},{"key":"key2017083010352486_ref1-bib34","volume-title":"Urgent Action Pledged on Over-Medication of People with Learning Disabilities","author":"NHS England"},{"key":"key2017083010352486_ref1-bib35","volume-title":"Psychotropic Drug Prescribing for People with Intellectual Disability, Mental Health Problems and\/or behaviours that Challenge: Practice Guidelines. Faculty Report FR\/ID\/09","author":"Faculty of Psychiatry of Intellectual Disability","year":"2016"},{"key":"key2017083010352486_ref1-bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2788.1996.tb00637.x","article-title":"Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities","volume":"40","author":"Branford","year":"1996","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib37","first-page":"165","article-title":"Factors associated with reduction in antipsychotic medication dosage in adults with mental retardation","volume":"98","author":"Luchins","year":"1993","journal-title":"Am J Ment Retard"},{"key":"key2017083010352486_ref1-bib38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1017\/S0790966700008417","article-title":"Withdrawal of antipsychotic drugs from adults with intellectual disabilities","volume":"21","author":"Stevenson","year":"2004","journal-title":"Ir J Psychol Med"},{"key":"key2017083010352486_ref1-bib39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1192\/bjp.176.1.42","article-title":"Reducing antipsychotic medication in people with a learning disability","volume":"176","author":"Ahmed","year":"2000","journal-title":"Br J Psychiatry"},{"key":"key2017083010352486_ref1-bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2215-0366(16)30191-2","article-title":"Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review","volume":"4","author":"Sheehan","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"key2017083010352486_ref1-bib41","volume-title":"Medicines for Human Use (Clinical Trials) Regulations","author":"Great Britain","year":"2004"},{"key":"key2017083010352486_ref1-bib42","volume-title":"Adaptive Behavior Scale: Residential and Community. Examiner\u2019s Manual","author":"Nihira","year":"1993"},{"key":"key2017083010352486_ref1-bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-3148.1997.tb00007.x","article-title":"Estimating IQ from adaptive behaviour information in people with moderate or severe intellectual disability","volume":"10","author":"Moss","year":"1997","journal-title":"J Appl Res Intellect Disabil"},{"key":"key2017083010352486_ref1-bib44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2788.1998.00146.x","article-title":"Reliability and validity of the Mini PAS-ADD for assessing psychiatric disorders in adults with intellectual disability","volume":"42","author":"Prosser","year":"1998","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib45","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1468-3148.2006.00346.x","article-title":"Modified Overt Aggression Scale (MOAS) for people with intellectual disability and aggressive challenging behaviour: a reliability study","volume":"20","author":"Oliver","year":"2007","journal-title":"J Appl Res Intellect Disabil"},{"key":"key2017083010352486_ref1-bib46","volume-title":"The Aberrant Behaviour Checklist","author":"Aman","year":"1986"},{"key":"key2017083010352486_ref1-bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2788.1998.00116.x","article-title":"Reliability and validity of the PAS-ADD checklist for detecting psychiatric disorders in adults with intellectual disability","volume":"42","author":"Moss","year":"1998","journal-title":"J Intellect Disabil Res"},{"key":"key2017083010352486_ref1-bib48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1017\/S1092852900022045","article-title":"An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists","volume":"6","author":"Dott","year":"2001","journal-title":"CNS Spectr"},{"key":"key2017083010352486_ref1-bib49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/1097-4679(199303)49:2<177::AID-JCLP2270490208>3.0.CO;2-#","article-title":"The Dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cutoff for mentally-ill and mentally-retarded populations","volume":"49","author":"Kalachnik","year":"1993","journal-title":"J Clin Psychol"},{"key":"key2017083010352486_ref1-bib50","first-page":"200","volume-title":"Measuring Mential Health Needs","author":"Beecham","year":"1992"},{"key":"key2017083010352486_ref1-bib51","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"key2017083010352486_ref1-bib52","volume-title":"Mental Capacity Act 2005","author":"Great Britain","year":"2005"},{"key":"key2017083010352486_ref1-bib53","volume-title":"Qualitative Methods for Health Research","author":"Green","year":"2004"},{"key":"key2017083010352486_ref1-bib54","volume-title":"Challenging Behaviour and Learning Disabilities: Prevention and Interventions for People with Learning Disabilities Whose Behaviour Challenges","author":"National Collaborating Centre for Mental Health","year":"2015"},{"key":"key2017083010352486_ref1-bib55","volume-title":"Psychotropic Drug Prescribing for People with Intellectual Disability, Mental Health Problems andor Behaviours that Challenge: Practice Guidelines","author":"Faculty of Psychiatry of Intellectual Disability","year":"2016"},{"key":"key2017083010352486_ref1-bib56","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s13063-016-1370-9","article-title":"Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): a pilot randomised controlled trial","volume":"17","author":"Cooper","year":"2016","journal-title":"Trials"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21470\/hta21470.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21470\/hta21470.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2010897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:49:53Z","timestamp":1692114593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta21470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":56,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2017,8]]}},"alternative-id":["10.3310\/hta21470"],"URL":"https:\/\/doi.org\/10.3310\/hta21470","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}